Track Adicet Bio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Adicet Bio, Inc. ACET · Stock Open Adicet Bio, Inc. in new tab

9.24 USD
EPS
-13.87
P/B
0.70
ROE
-72.19
Beta
1.59
Target Price
35.50 USD
Loading chart...
Key Metrics
Earnings dateAug. 6, 2026
EPS-13.87
Book Value13.03
Price to Book0.70
Debt/Equity9.92
% Insiders1.079%
Estimates
Forward P/E-2.61
Forward EPS-3.49
Target Mean Price35.50

DCF Valuation

Tweak assumptions to recompute fair value for Adicet Bio, Inc. (ACET)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Adicet Bio, Inc. Logo Adicet Bio, Inc. Analysis (ACET)

United States Health Care Official Website Stock

Is Adicet Bio, Inc. a good investment? Adicet Bio, Inc. (ACET) is currently trading at 9.24 USD. Market analysts have a consensus price target of 35.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Adicet Bio, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -3.49.

Investor FAQ

Does Adicet Bio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Adicet Bio, Inc.?

Adicet Bio, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -13.87.

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Exchange Ticker
NMS (United States) ACET
PAR (France) EUR.PA
FRA (Germany) 1IJA.F
LSE (United Kingdom) 0HX7.L
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
2018
0.00 USD
Oct. 9, 2018 0.0001
June 22, 2018 0.0001
March 23, 2018 0.0006
2017
0.00 USD
Dec. 28, 2017 0.0006
Sept. 21, 2017 0.0006
June 23, 2017 0.0006
March 24, 2017 0.0006
2016
0.00 USD
Dec. 22, 2016 0.0006
Sept. 20, 2016 0.0006
June 24, 2016 0.0005
March 25, 2016 0.0005
2015
0.00 USD
Dec. 28, 2015 0.0005
Oct. 2, 2015 0.0005
June 25, 2015 0.0005
March 26, 2015 0.0005
2014
0.00 USD
Dec. 29, 2014 0.0005
Sept. 29, 2014 0.0005
June 27, 2014 0.0005
March 28, 2014 0.0005
2013
0.00 USD
Dec. 27, 2013 0.0005
Sept. 27, 2013 0.0005
June 25, 2013 0.0005
March 26, 2013 0.0005
2012
0.00 USD
Dec. 28, 2012 0.0005
Sept. 28, 2012 0.0005
June 22, 2012 0.0009
Jan. 18, 2012 0.0009
2011
0.00 USD
June 24, 2011 0.0009
Jan. 21, 2011 0.0009
2010
0.00 USD
June 25, 2010 0.0009
Jan. 15, 2010 0.0009
2009
0.00 USD
June 26, 2009 0.0009
Stock Splits
Split Date Split Ratio to 1
Sept. 16, 2020 0.140000
Dec. 30, 2025 0.060000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion